All You Need to Know About Microbot Medical (MBOT) Rating Upgrade to Buy

Core Viewpoint - Microbot Medical Inc. (MBOT) has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system reflects changes in earnings estimates, which are strongly correlated with stock price movements, particularly due to institutional investors adjusting their valuations based on these estimates [4][6]. - For the fiscal year ending December 2025, Microbot Medical is expected to earn -$0.30 per share, unchanged from the previous year, but the Zacks Consensus Estimate has increased by 6.3% over the past three months [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - The upgrade to Zacks Rank 2 places Microbot Medical in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [10].